Stayble Therapeutics is a clinical pharmaceutical company developing an injection-based treatment against lumbar disc herniation (LDH) using the drug candidate STA363
Stayble Therapeutics is a clinical pharmaceutical company developing an injection-based treatment against lumbar disc herniation (LDH) using the drug candidate STA363. This minimally invasive treatment aims to reduce disc volume and relieve nerve pressure for patients who have not responded to traditional therapies.